Alzheon, Inc. vs Risen (Suzhou) Pharma Tech Co., Ltd.

Other: Fed Circuit mandate

Other: other court decision

Order: on Motion

Petitioners Unopposed Motion to Withdraw and Substitute Counsel

EXPUNGED

EXPUNGED

Granting Patent Owner Motion to Withdraw and Substitute Counsel 37 C.F.R. § 42.10

Exhibit 3004

Patent Owner's Unopposed Motion to Withdraw Certain Counsel

Patent Owner's Updated Power of Attorney

Patent Owner's Notice of Appeal

Final Written Decision: original

Other: Hearing transcript

LEAP Practitioner Request and Verification Form (Petitioner)

LEAP Practitioner Request and Verification Form (Patent Owner)

Petitioners Third Updated Exhibit List

Petitioner Alzheon Demonstrative

Patent Owner's Demonstrative Exhibits

Notice of Filing Demonstrative Exhibits

Order: Granting Request for Oral Hearing

Petitioners Reply to Opposition to Motion to Exclude Kimball Declaration

Patent Owner's Opposition to Petitioner's Motion to Exclude

Patent Owner's Third Updated Mandatory Notices

Petitioners Sur-reply to Opposition to Contingent Motion to Amend

Petitioners Motion to Exclude Kimball Declaration

Transcript of March 30, 2022 Deposition of Peter Guengerich

Patent Owner's Sur-Reply

Patent Owner's Reply to Petitioner's Opposition to the Contingent Motion to Amend

Notice: PRELIMINARY GUIDANCE PATENT OWNERS MOTION TO AMEND

Notice of Deposition of F. Peter Guengerich, Ph.D.

Patent Owner's Objections to Petitioner's Reply Evidence

Petitioners Reply to Patent Owner Response

Petitioners Opposition to Contingent Motion to Amend

Petitioners Second Updated Exhibits List

Corrections to Sessler Declaration

WO2017_044840

Harbeson_2014

Ma_2012

CAS Reaction Search

Guengerich Reply Declaration

Guengerich Transcript Errata

Sessler Deposition Transcript

Errata to Sessler Deposition Transcript

Manzano 2020

Martorana 2014

Spalletta 2016

Bossu 2018

Abushakra 2017

Sabbagh 2017

Martorana 2018

Galarneau 2007

Azzi 2007

Janssens de Varebeke 1988

Matsukawa 2004

Fieser 1967

Wade

March

Mullard 2016

Teva

Guengerich 2020

De Strooper 2014

Sharma 2012

Kimball Deposition Transcript

Errata to Kimball Deposition Transcript

Kurtz 1997

Walsh

Cook 2007

Petitioner's Request For Oral Argument

Patent Owner's Request for Oral Hearing

REVISED SCHEDULING ORDER 37 C.F.R. sec 42.5

Email From: Trials To: [email protected]; Trials Cc: [email protected]; [email protected]; Michelle K. Nyein Subject: RE: IPR2021-00347 Due Date 2 and Petitioner"s Opposition to Contingent MTA Date: February 9, 2022

Joint Notice of Stipulation to Fourth Revised Schedule

Petitioners Notice of Deposition of S. David Kimball, Ph.D.

Petitioners Objections to Exhibits 2099-2100

Order: Conduct of the Proceeding: Granting Patent Owners Request to Substitute the Declaration of Dr. Steven Wagner 37 C.F.R. § 42.5

Exhibit 3002

Declaration of S. David Kimball, Ph.D.

Curriculum Vitae of S. David Kimball, Ph.D.

Notice of Filing Declaration of S. David Kimball Ph.D.

Joint Notice of Stipulation to Third Revised Schedule

Joint Notice of Stipulation to Second Revised Schedule

Petitioners Notice of Deposition of Steven L Wagner PhD

Joint Notice of Stipulation to Revised Schedule

Petitioners Notice of Deposition of Jonathan L Sessler PHD

Patent Owner's Second Updated Mandatory Notices

CAS Registry Entry for Tramiprosate

CAS Registry Entry for D2-tramiprosate

CAS Registry Entry for Val-APS

CAS Registry Entry for D2-Val-APS

Aisen et al., Arch Med Sci, 7(1):102-11 (2011)

Singh et al., J Clin Diagn Res, 7(11):2555-8 (2013)

Liu et al., Annual Reports in Medicinal Chemistry, 50:519-542 (2017)

Memorandum, Dept of Health & Human Services

Husain et al., Biochemistry, 21(3):595-600 (1982)

Deutetrabenazine (Austedo) Division Director Summary Review for Regulatory Action (March 2017)

Harbeson et al., J Pharmacol Exp Ther, 362(2):359-367 (2017)

Transcript of September 28, 2021 Deposition of Peter Guengerich

Curriculum Vitae of Jonathan L. Sessler, Ph.D.

CAS FAQs, Chem. Abstracts Serv.

Helfenbein et al., J. Med. Chem, 45(26):5806-8 (2002)

Thomson, Annals of the New York Academy of Sciences, 84(16):736-744 (1960)

Schofield et al., Bioorg Med Chem, 23(13):3831-42 (2015)

Qiao et al., Epilepsia, 41(6):655-65 (2000)

Finberg et al., Front Pharmacol, 7:340 (2016)

Fisher et al., Curr Opin Drug Discov Devel, 9(1):101-9 (2006)

Saivin et al., Clin. Pharmacokinet, 35:331-345 (1998)

Dunsaed et al., Int J Oncol, 2(1):61-6 (1993)

Manley et al., Bioorg Med Chem, 21(11):3231-9 (2013)

Perez-Gomez et al., J Clin Med, 4(6):1325-47 (2015)

Clinical Trial Records for CTP-499, U.S. National Library of Medicine (October 6, 2021)

U.S. Pat. No. 9,249,149

Fukuto et al., J Med Chem, 34(9):2871-6 (1991)

Krauser et al., J Biol Chem, 280(20):19496-506 (2005)

Shao et al., Drug News Perspect, 23(6):398-404 (2010)

Guengerich, J Labelled Comp Radiopharm, 56(9-10):428-31 (2013)

Atkins et al., J. Am. Chem. Soc., 109(12):3754-3760 (1987)

Nelson et al., Drug Metab Dispos, 31(12):1481-98 (2003)

Xu et al., J Med Chem, 57(4):1236-51 (2014)

Sharma et al., Drug Metab Dispos, 40(3):625-34 (2012)

Abad et al., J Phys Chem B., 117(46):14238-46 (2013)

U.S. Patent Application No. 15/476,255 (as filed March 31, 2017) ("the '255 application")

U.S. Pat. No. 10,954,188 ("the '311 application")

Declaration of Steven L. Wagner, Ph.D.

Curriculum Vitae of Steven L. Wagner, Ph.D.

Iwatsubo et al., Neuron, 13(1):45-53 (1994)

Jarrett et al., Biochemistry, 32(18):4693-7 (1993)

Bitan et al., Proc Natl Acad Sci U S A, 100(1):330-5 (2003)

De Jonghe et al., Hum Mol Genet, 10(16):1665-71 (2001)

Gervais et al., Neurobiol Aging, 28(4):537-47 (2007)("Gervais")

Young et al., Nat Chem 7(1):73-81 (2015) ("Young")

Dobson, Nature, 426(6968):884-90 (2003)

Hellstrand et al., ACS Chem Neurosci, 1(1):13-8 (2010)

Christi et al., J Biol Chem, 276(24):21562-70 (2001)

Aisen et al., Neurology, 67(10):1757-63 (2006)

Fagan et al., Ann Neurol, 59(3):512-9 (2006)

Abushakra et al., J Prev Alzheimers Dis, 3(4):219-228 (2016)

Kounnas et al., Neuron, 67(5):769-80 (2010)

Toyn et al., J Pharmacol Exp Ther, 358(1):125-37 (2016)

May et al., J Neurosci, 35(3):1199-210 (2015)

Kennedy et al., Sci Transl Med, 8(363):363ra150 (2016)

Santa-Maria et al., Mol Neurodegener, 2(17):1-12 (2007)

Swanoski, Am J Health Syst Pharm, 66(21):1950-3 (2009)

Declaration of Rachel J. Watters

U.S. Pat. No. 8,304,435

U.S. Pat. No. 8,669,275

U.S. Pat. No. 8,557,994

U.S. Pat. No. 9,453,027

U.S. Pat. No. 8,927,553

U.S. Pat. No. 9,464,066

Deutetrabenazine (Austedo) Clinical Pharmacology and Biopharmaceutical Review (April 2016) - Part 1 of 3

Deutetrabenazine (Austedo) Clinical Pharmacology and Biopharmaceutical Review (April 2016) - Part 2 of 3

Deutetrabenazine (Austedo) Clinical Pharmacology and Biopharmaceutical Review (April 2016) - Part 3 of 3

Rowley et al., J Med Chem, 40(25):4053-68 (1997)

Second Declaration of Curtis Powell

SEC filings, Teva Pharmaceutical Industries Ltd.

Declaration of Jonathan L. Sessler, Ph.D.

Patent Owner Response

Patent Owner's Contingent Motion to Amend

Information and Guidance on Motion to Amend

Notice of Deposition of F. Peter Guengerich, Ph.D.

Patent Owner's First Updated Mandatory Notices

Petitioners Objections to Patent Owners Exhibits Filed With Preliminary Response

Patent Owner's Objections to Evidence

Granting Petitioner���s Motion for Admission pro hac vice of Lee Carl Bromberg 37 C.F.R. sec. 42.10

Decision Granting Institution of Inter Partes Review

SCHEDULING ORDER

EXPUNGED

Patent Owner's Preliminary Response

Selkoe, Nature Medicine, 17(9):1060-65 (2011)

Hung et al., J. Biomedical Science, 24:47 (2017)

Karran et al., Annals of Neurology, 76(2):185-205 (2014)

Habchi et al., Science Advances, 2(2): e1501244 (2016)

Briggs et al., Clinical Medicine, 16(3):247-253 (2016)

Cummings et al., Alzheimer's & Dementia, 2(4):222-232 (2016)

Godyn et al., Pharmacological Reports, 68(1):127-38 (2015)

U.S. Pat. No. 10,413,546 ("Nishino")

U.S. Pat. No. 9,980,937

U.S. Pat. No. 10,106,524

U.S. Pat. No. 10,159,816

U.S. Pat. No. 10,188,636

U.S. Pat. No. 10,239,923

U.S. Pat. No. 10,246,468

U.S. Pat. No. 10,342,807

U.S. Pat. No. 10,391,079

U.S. Pat. No. 10,413,546

U.S. Pat. No. 10,603,311

U.S. Pat. No. 10,654,917

US Pub. No.: US 2016/0331721

US Pub. No.: US 2019/0365771

US Pub. No.: US 2020/0338040

Int. Pub. No.: WO 2016/182812

Int. Pub. No.: WO 2017/055540

Tofthagen, J. of the Advanced Practitioners in Oncology, 3(3):181-183 (2012)

Excerpts from the '323 Patent File History

Clinical Trial Records for ALZ-801, U.S. National Library of Medicine (Apr. 14, 2021)

Rothwell, Lancet, 356(9454):176-86 (2005)

Petitioners Motion For Pro Hac Vice Admission

Petitioners First Updated Exhibit List

EX1040_Bromberg_Declaration

Notice of Accord Filing Date

Patent Owner's Mandatory Notices

Patent Owner's Power of Attorney

PETITION FOR INTER PARTES REVIEW OF US PATENT NO. 10,472,323

Guengerich_Declaration

Guengerich_CV

US8748656_Kong

US20100120744_Gant

Morgan

Foster

ALZHEON INC POWER OF ATTORNEY

FEE AUTHORIZATION

US10472323_LU

323_Patent_File_History

US20090076167_Czarnik

US10471029_Tolar

US7517990_Ito

Atkins

CRC_Handbook

Dyck

Anslyn

US20120214745_Naicker

Browne

Anderson

Hennig

Belleau

Qiu

Mayer

US6603008_Ando

OLeary

Caldwell

Soper

Yu1986

Guengerich2017

Feldman

Burnett

Yu1987

Rishavy

Walsh

Miller

Yoval-Sanchez

Guengerich2008

Press_Release

Courtyn

Keyl_Declaration